| Dr Stanley E Waintraub, MD | |
|
92 2nd St, Hackensack, NJ 07601-2191 | |
| (551) 996-5864 | |
| (551) 996-0578 |
| Full Name | Dr Stanley E Waintraub |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 47 Years |
| Location | 92 2nd St, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609835586 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0000X | Internal Medicine - Hematology | 25MA04179800 (New Jersey) | Secondary |
| 207RX0202X | Internal Medicine - Medical Oncology | 25MA04179800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Cancer Care Associates Llc | 5294710091 | 104 |
News Archive
Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Pivotal, a European-wide full-service CRO, has announced today that it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from cured and convalescent COVID-19 patients, in the treatment of hospitalized patients with COVID-19 who are admitted in an acute phase.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
If it seems like your stomach has a mind of its own, you're not wrong. University of Cincinnati assistant professor Ashley Ross says your body is full of neurons that regulate digestion, inflammation and a host of other biological processes.
› Verified 7 days ago
| Entity Name | Regional Cancer Care Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801850243 PECOS PAC ID: 5294710091 Enrollment ID: O20040623001494 |
News Archive
Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Pivotal, a European-wide full-service CRO, has announced today that it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from cured and convalescent COVID-19 patients, in the treatment of hospitalized patients with COVID-19 who are admitted in an acute phase.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
If it seems like your stomach has a mind of its own, you're not wrong. University of Cincinnati assistant professor Ashley Ross says your body is full of neurons that regulate digestion, inflammation and a host of other biological processes.
› Verified 7 days ago
| Entity Name | Totowa Cancer Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225777808 PECOS PAC ID: 0446615835 Enrollment ID: O20230509001361 |
News Archive
Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Pivotal, a European-wide full-service CRO, has announced today that it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from cured and convalescent COVID-19 patients, in the treatment of hospitalized patients with COVID-19 who are admitted in an acute phase.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
If it seems like your stomach has a mind of its own, you're not wrong. University of Cincinnati assistant professor Ashley Ross says your body is full of neurons that regulate digestion, inflammation and a host of other biological processes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stanley E Waintraub, MD 92 2nd St, Hackensack, NJ 07601-2191 Ph: () - | Dr Stanley E Waintraub, MD 92 2nd St, Hackensack, NJ 07601-2191 Ph: (551) 996-5864 |
News Archive
Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Pivotal, a European-wide full-service CRO, has announced today that it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from cured and convalescent COVID-19 patients, in the treatment of hospitalized patients with COVID-19 who are admitted in an acute phase.
Parion Sciences, a company dedicated to the development of novel treatments for ocular and pulmonary diseases, announced today that it has received acceptance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for P-321 Ophthalmic Solution for the treatment of dry eye disease.
If it seems like your stomach has a mind of its own, you're not wrong. University of Cincinnati assistant professor Ashley Ross says your body is full of neurons that regulate digestion, inflammation and a host of other biological processes.
› Verified 7 days ago
Dr. Sean Shabbir Sadikot, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 707, Hackensack, NJ 07601 Phone: 551-996-2211 Fax: 551-996-5727 | |
Mr. Angel J Mulkay, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 493 Essex Avenue, Hackensack, NJ 07601 Phone: 201-996-9244 Fax: 201-601-0995 | |
Dr. Morris Samuel Friedman, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 52 1st St, Hackensack, NJ 07601 Phone: 201-342-0066 Fax: 201-342-0079 | |
Dr. David Serur, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Prospect Ave Ste 406, Hackensack, NJ 07601 Phone: 551-996-2608 Fax: 551-996-0826 | |
Jerome F Levine, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 20 Prospect Ave, Suite 507, Hackensack, NJ 07601 Phone: 201-487-4088 | |
Dr. Noa Biran, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 2nd St, Hackensack, NJ 07601 Phone: 551-996-8704 Fax: 551-996-0582 | |
Naresh Chanderi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 344 Prospect Ave, Hackensack, NJ 07601 Phone: 201-342-4233 Fax: 201-342-4840 |